Join Date
November 2022
Country
Gender
Not Specified
Age
Not Specified
About Dan Meyer
Daniel Meyer is the CEO of CellChorus, the leader in providing high-throughout dynamic single-cell analysis to the life sciences industry.
Dan was the Chief Operating Officer and a board member of Genospace until its acquisition by HCA Healthcare (NYSE:HCA). He was a member of the venture capital investment teams at Arboretum Ventures and PJC.vc.
Dan holds a B.A. in mathematics and economics from Middlebury College and an M.B.A. from the Tuck School of Business at Dartmouth.
Dan was the Chief Operating Officer and a board member of Genospace until its acquisition by HCA Healthcare (NYSE:HCA). He was a member of the venture capital investment teams at Arboretum Ventures and PJC.vc.
Dan holds a B.A. in mathematics and economics from Middlebury College and an M.B.A. from the Tuck School of Business at Dartmouth.
Companies & Work
CellChorus
At CellChorus, we apply artificial intelligence to evaluate thousands of microscopy videos in parallel to evaluate how immune cells move, interact and perform over time. This allows our customers to discover, develop, manufacture and deliver cell therapies, antibodies, vaccines and other novel therapies faster, at lower expense, and with higher rates of success.
Our customers include top-25 biopharma companies and seed-stage biotechs that are developing cell therapies, antibody therapeutics and vaccines (including one of the few companies with an approved CAR T cell therapy).
Hear from the team at https://www.youtube.com/watch?v=IE9x_tm0XnI
Our customers include top-25 biopharma companies and seed-stage biotechs that are developing cell therapies, antibody therapeutics and vaccines (including one of the few companies with an approved CAR T cell therapy).
Hear from the team at https://www.youtube.com/watch?v=IE9x_tm0XnI
